Existing data have shown that the downregulation of Fas expression could be detected in many types of human tumors [30, 31], and the dysregulation of Fas has been demonstrated to be related to the risk of developing ovarian cancer as well as to the survival of patients treated with platinum-based chemotherapy [32]. Here, FAS is linked to ovarian carcinoma.